Telix Pharmaceuticals
$9.35
101
+$0.74+8.59% Tuesday 15:32
Statistics
Day High
8.61
Day Low
8.61
52W High
19.99
52W Low
5.91
Volume
1,200
Avg. Volume
3,279
Mkt Cap
3.17B
P/E Ratio
512.5
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19FebExpected
Expected EPS
0.046411506469999995
Actual EPS
-0.016430355999999997
Financials
-0.89%Profit Margin
Unprofitable1.07BRevenue
-9.48MNet Income
Analyst Ratings
$21.25Average Price Target
The highest estimate is 22.50.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TLPPF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
ClearPoint Neuro
CLPT
Mkt Cap660.08M
Novartis
NVS
Mkt Cap237.61B
Bausch Health Companies
BHC
Mkt Cap2.62B
Protagonist Therapeutics
PTGX
Mkt Cap4.89B
Dr. Reddy`s Laboratories
RDY
Mkt Cap11.25B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Pfizer
PFE
Mkt Cap140.15B
About
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Show more...
CEO
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
Employees
415
Country
AU
ISIN
AU000000TLX2
Listings
0 Comments
Share your thoughts
FAQ
What is Telix Pharmaceuticals stock price today?▼
The current price of TLPPF is $9.35 USD — it has increased by +8.59% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.
What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Telix Pharmaceuticals stocks are traded under the ticker TLPPF.
Is Telix Pharmaceuticals stock price growing?▼
TLPPF stock has risen by +4.7% compared to the previous week, the month change is a +27.12% rise, over the last year Telix Pharmaceuticals has showed a -43.25% decrease.
What is Telix Pharmaceuticals market cap?▼
Today Telix Pharmaceuticals has the market capitalization of 3.17B
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on August 20, 2026.
What were Telix Pharmaceuticals earnings last quarter?▼
TLPPF earnings for the last quarter are -0.01 USD per share, whereas the estimation was 0.03 USD resulting in a -135.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Telix Pharmaceuticals revenue for the last year?▼
Telix Pharmaceuticals revenue for the last year amounts to 1.07B USD.
What is Telix Pharmaceuticals net income for the last year?▼
TLPPF net income for the last year is -9.48M USD.
How many employees does Telix Pharmaceuticals have?▼
As of April 01, 2026, the company has 415 employees.
In which sector is Telix Pharmaceuticals located?▼
Telix Pharmaceuticals operates in the Health Care sector.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, AU.